Berlex Laboratories, Inc.

Schering Aktiengesellschaft

Intermune, Inc.

Blade Therapeutics, Inc.

Array Biopharma Inc.

Bayer Schering Pharma Ag

Schering Aktiengessellschaft

Brad Owen Buckman

Michael M Morrissey

Wei Xu

Howard P Ng

Imadul Islam

Raju Mohan

Shendong Yuan

Guo Ping Wei

Gary Bruce Phillips

David D Davey

William J Guilford

Shung C Wu

John Beamond Nicholas

Karen B May

Kumaraswamy Emayan

Scott D Seiwert

Judi Bryant

Sean D Monahan

Meina Liang

John G Bauman

Richard Horuk

Joseph E Hesselgesser

Ameen F Ghannam

Wei Zheng

Zuchun Zhao

Kenneth Jay Shaw

Johnnie Y Ramphal

Marc Adler

Jingyuan Ma

Leonid Beigelman

John T Martin

Andrew I Chitty

Christopher West

Kumar Emayan

Steven Wade Andrews

Yutong Jiang

Hans Briem

Kevin Ronald Condroski

Dirk Kosemund

Joachim Kuhnke

Timothy S Kercher

Bin Wang

Monica J Kochanny

Lawrence M Blatt

Damian O Arnaiz

Antitsa Dimitrova Stoycheva

Williamson Ziegler Bradford

Vladimir Serebryany

Richard L Feldman

Michael Lyon

Peter Esperling

Lars Wortmann

April L Kennedy

Christoph Huwe

Seock-Kyu Khim

Robert J Kaus

Steven B Porter

Emil Eckle

Robert Guo-Ping Wei

Ulf Bomer

Michael Morrissey

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

Calpain modulators and therapeutic uses thereof

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic &#x3b1;-keto amide derivatives and their use as therapeutic agents.

Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.

Anti-fibrotic pyridinones

The present technology relates to cyclic keto-amide compounds of general formulae I to XXXII, compositions and kits thereof as calpain modulators and methods useful for the treatment of various diseases or disorders such as fibrotic disease or cancer which are associated or mediated, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is also applicable to cyclic keto-amide compounds which inhibit myofibroblast differentiation.

Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

Lysophosphatidic acid receptor antagonists

The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Macrocyclic inhibitors of hepatitis C virus replication

Compounds of the following formula (I), for example: wherein R, R, R, and Rare described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

Plasma carboxypeptidase B inhibitors

The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Peptide inhibitors of hepatitis C virus replication

Compounds of the following formula (I), for example: (1), wherein R, R, R, and Rare described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein. 

Growing community of inventors

Oakland, CA, United States of America

Brad Owen Buckman